A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
Metastatic Castration-resistant Prostate Cancer
DRUG: BMS-986460
Number of participants with adverse events (AEs), Up to 112 weeks|Number of participants with serious adverse events (SAEs), Up to 112 weeks|Number of participants with AEs meeting protocol defined dose limiting toxicity (DLT) criteria, Up to 28 days|Number of participants with AEs leading to study intervention discontinuation, Up to 104 weeks|Number of deaths, Up to 212 weeks
Maximum concentration (Cmax), Up to 13 weeks|Time of maximum concentration (Tmax), Up to 13 weeks|Area under the plasma concentration-time curve (AUC), Up to 13 weeks|Number of participants with a confirmed prostate specific antigen decline of â‰¥ 30% from baseline response rate, Up to 108 weeks|Number of participants with soft tissue response, Up to 108 weeks|Duration of response (DOR), Up to 108 weeks
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.